We are live on ! Find out more
WINT

Windtree Therapeutics
WINT

Delisted

WINT was delisted on the 20th of August, 2025.

Back to rankings

5 hedge funds and large institutions have $8.75K invested in Windtree Therapeutics in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0% more funds holding

Funds holding: 5 → 5 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

5.57% less ownership

Funds ownership: 6.04% → 0.46% (-5.6%)

85% less capital invested

Capital invested by funds: $57K → $8.75K (-$48.3K)

Holders
5
Holders Change
–
Holders Change %
0%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$12.9K
2
TRCT
Tower Research Capital (TRC)
New York
+$741
3
Bank of America
Bank of America
North Carolina
+$3

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$25.5K
2
Morgan Stanley
Morgan Stanley
New York
-$18.9K

WINT Hedge Fund Activity: Q2 2025 in Review

5 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Windtree Therapeutics (WINT) for Q2 2025, worth a combined $8.75K — down 85% from $57K a quarter earlier.

Fund positioning in WINT was balanced in Q2 2025: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 1 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $12.9K. The largest seller was UBS Group, cutting an estimated $25.5K.

  • 5 institutional investors held Windtree Therapeutics (WINT) as of Q2 2025, unchanged from Q1 2025.
  • Funds reported $8.75K of Windtree Therapeutics stock for Q2 2025, down 85% quarter-over-quarter.
  • 1 fund opened new Windtree Therapeutics positions in Q2 2025 and 1 closed out, a net change of 0 holders.
  • The largest Windtree Therapeutics buyer in Q2 2025 was Jane Street, an estimated $12.9K added.
  • The largest Windtree Therapeutics seller in Q2 2025 was UBS Group, an estimated $25.5K sold.

Based on aggregated 13F filings for Q2 2025.